Genentech
Founded Year
1976Stage
Acq - P2P | AcquiredTotal Raised
$100KValuation
$0000
- Predict emerging trends
- See competitors' playbooks
- Stalk the smart money
- Identify tomorrow's challengers
- Spot growing industries
- Kill analyst data work
Research containing Genentech
Get data-driven expert analysis from the CB Insights Intelligence Unit.
CB Insights Intelligence Analysts have mentioned Genentech in 2 CB Insights research briefs, most recently on Aug 3, 2021.
Genentech Patents
Genentech has filed 2436 patents.
The 3 most popular patent topics include:
- Clusters of differentiation
- Monoclonal antibodies
- Transcription factors
Application Date | Grant Date | Title | Related Topics | Status |
|---|---|---|---|---|
8/15/2019 | 9/19/2023 | Proteins, Transcription factors, Signal transduction, Human proteins, Pyridines | Grant |
Application Date | 8/15/2019 |
|---|---|
Grant Date | 9/19/2023 |
Title | |
Related Topics | Proteins, Transcription factors, Signal transduction, Human proteins, Pyridines |
Status | Grant |
Latest Genentech News
Sep 24, 2023
Receive an email when new articles are posted on Please provide your email address to receive an email when new articles are posted on . Please try again later. If you continue to have this issue please contact customerservice@slackinc.com . An estimated 288,300 men in the United States will be diagnosed with prostate cancer this year and about 34,700 men will die of the disease, according to American Cancer Society. An estimated 288,300 men in the United States will be diagnosed with prostate cancer this year and about 34,700 men will die of the disease, according to American Cancer Society. Image: Adobe Stock National Prostate Cancer Awareness Month is intended to educate men about prostate cancer risk factors, screening and treatment options. In conjunction with the observance, Healio presents the following updates in prostate cancer research that may be relevant to your practice. 1. More than half of men treated for metastatic prostate cancer reported experiencing some degree of financial hardship. Read more . 2. Researchers discovered a biological mechanism among men with diabetes and metastatic prostate cancer that they believe may lay the foundation for better testing and treatments for Black men with both diseases. Read more . 3. Shared decision-making could attenuate racial disparities in prostate cancer screening. Read more . 4. The combination of cabozantinib (Cabometyx, Exelixis) and atezolizumab (Tecentriq, Genentech) prolonged PFS compared with second novel hormonal therapy for men with metastatic castration-resistant prostate cancer. Read more . 5. The FDA approved niraparib and abiraterone acetate (Akeega, Janssen Biotech) with prednisone for the treatment of deleterious or suspected deleterious BRCA-mutated castration-resistant prostate cancer. Read more . 6. Men with very high-risk prostate cancer treated at high-volume radiation therapy treatment facilities survived significantly longer than those treated at low-volume centers. Read more . 7. Black men with metastatic castration-sensitive prostate cancer achieved OS and PFS comparable to white men when treated in a clinical trial setting. The findings suggest equal access to health care resources can help alleviate racial disparities in survival among Black men with advanced prostate cancer. Read more . 8. Supervised resistance and aerobic exercise appeared to improve sexual function among men with prostate cancer. Read more . 9. Magnetic resonance-guided daily adaptive stereotactic body radiotherapy appeared associated with a reduction in acute toxicity compared with a more common technique for men with prostate cancer. Read more . 10. The FDA approved talazoparib (Talzenna, Pfizer) plus enzalutamide (Xtandi; Astellas, Pfizer) for treatment of homologous recombination repair gene-mutated metastatic castration-resistant prostate cancer. Read more . Reference:
Genentech Frequently Asked Questions (FAQ)
When was Genentech founded?
Genentech was founded in 1976.
Where is Genentech's headquarters?
Genentech's headquarters is located at One DNA Way, South San Francisco.
What is Genentech's latest funding round?
Genentech's latest funding round is Acq - P2P.
How much did Genentech raise?
Genentech raised a total of $100K.
Who are the investors of Genentech?
Investors of Genentech include Roche, H&Q Asia Pacific, Sofinnova Ventures, Mayfield, InnoVen Capital and 3 more.
Who are Genentech's competitors?
Competitors of Genentech include Healios and 5 more.
- Predict emerging trends
- See competitors' playbooks
- Stalk the smart money
- Identify tomorrow's challengers
- Spot growing industries
- Kill analyst data work
Compare Genentech to Competitors
Konectom is a mobile application to improve the assessment of neurological diseases. Its application suite contains self-assessments for clinical study participants living with neurological impairments, consisting of tests covering ambulation, dexterity, and cognition. It is based in Cambridge, Massachusetts.
Civica Rx is a not-for-profit generic drug company that will help patients by addressing shortages and high prices of lifesaving generic medications.
Syntr Health Technologies specializes in the micro fragmentation of adipose tissue for body contouring. The company's device transfers autologous adipose tissue to reverse the medical effects of the aging process. The company was founded in 2016 and is based in Irvine, California.
HAPLN Science is a drug development company that focuses on anti-aging therapies that can reverse tissue and organ degeneration. The company's products include treatments for degenerative arthritis, skin aging treatment, hair loss, and connective tissue disease. HAPLN Science was founded in 2018 and is based in Seongnam, South Korea.
FoodMarble develops a personal digestive health tracker. It provides technology to help patients and consumers to measure their meals, stress, sleep, and symptoms and test their fermentation level with personalized, real-time results based on validated clinical technology with a tiny breath test device application. The company was founded in 2016 and is based in Dublin, Ireland.
AbbVie (NYSE: ABBV) researches and develops pharmaceutical products. The company produces pharmaceutical drugs for specialty therapeutic areas such as immunology, chronic kidney disease, hepatitis C, women's health, oncology, and neuroscience. It also offers treatments for diseases including multiple sclerosis, Parkinson's, and Alzheimer's disease. The company was founded in 2013 and is based in North Chicago, Illinois.
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.
